ADC Therapeutics SA Cash Flow-to-Debt Ratio
ADC Therapeutics SA cash flow-to-debt ratio. ADC Therapeutics SA (ADCT) has a Cash Flow-to-Debt Ratio of -0.06x as of March 2026, meaning its operating cash flow of $-29.71 Million could theoretically repay 0% of its total liabilities ($507.87 Million) in one year. Check ADCT capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ADC Therapeutics SA (2017–2025)
Cash flow-to-debt ratio of ADC Therapeutics SA from 2017 to 2025. Historical debt coverage capacity for ADC Therapeutics SA across 9 annual periods. See ADC Therapeutics SA (ADCT) balance sheet quality index to measure how much of total assets are equity-financed.
ADC Therapeutics SA Cash Flow-to-Debt Ratio by Year (2017–2025)
ADC Therapeutics SA cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for ADC Therapeutics SA. For the full cash flow conversion analysis, see ADC Therapeutics SA cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.28x | $-141.17 Million | $508.98 Million | ▼ -17.5% |
| 2024 | -0.24x | $-123.83 Million | $524.62 Million | ▼ 0.0% |
| 2023 | -0.24x | $-118.69 Million | $503.03 Million | ▲ +29.8% |
| 2022 | -0.34x | $-138.31 Million | $411.41 Million | ▲ +34.9% |
| 2021 | -0.52x | $-233.38 Million | $451.88 Million | ▲ +45.5% |
| 2020 | -0.95x | $-168.73 Million | $178.19 Million | ▲ +79.3% |
| 2019 | -4.58x | $-121.58 Million | $26.53 Million | ▲ +8.2% |
| 2018 | -4.99x | $-121.36 Million | $24.32 Million | ▼ -51.7% |
| 2017 | -3.29x | $-74.94 Million | $22.78 Million | — |